Capmatinib
Tabrecta (capmatinib) is a prescription brand-name medication used to treat adults with a specific type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It is specifically approved for patients whose tumors have MET exon 14 skipping mutations. This is an oral targeted therapy that requires a companion diagnostic test to identify eligible patients before treatment.
Tabrecta is an oral targeted therapy for advanced non-small cell lung cancer with MET exon 14 skipping mutations.
Key facts at a glance
- RxNorm
- 2362235
- Generic
- Tabrecta
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have MET exon 14 skipping mutations. This medication is used when the cancer has spread (metastasized) and requires confirmation of the specific genetic mutation through testing before initiation.
Tabrecta is a MET tyrosine kinase inhibitor. It works by blocking the activity of the MET protein, which is involved in cell growth and survival. In cancers with MET exon 14 skipping mutations, this protein becomes abnormally active, contributing to tumor growth and progression. By inhibiting this protein, Tabrecta helps slow or stop cancer cell growth.
Tabrecta is a brand-name medication with no generic equivalent currently available. Common side effects may include swelling, fatigue, nausea, and liver enzyme elevations. Patients should be monitored for liver function and lung symptoms during treatment. Drug interactions are possible, and patients should inform their healthcare provider of all medications and supplements they are taking.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy